D 21266,
D-21266,
octadecyl-(1,1-dimethyl-4-piperidylio)phosphate,
perifosine,
Perifosine,
157716-52-4,
1,1-Dimethylpiperidin-1-ium-4-yl octadecyl phosphate,
KRX-0401,
NSC 639966,
(1,1-dimethylpiperidin-1-ium-4-yl) octadecyl phosphate,
Perifosine (KRX-0401),
D 21266,
NSC639966,
1,1-dimethylpiperidinium-4-yl octadecyl phosphate,
UNII-2GWV496552,
KRX 0401,
CHEBI:67272,
4-((Hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethylpiperidinium inner salt,
2GWV496552,
NSC-639966,
NCGC00187909-01,
AK-48419,
Piperidinium, 4-[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt,
J-500086,
Piperidinium, 4-((hydroxy(octadecyloxy)phosphinyl)oxy)-1,1-dimethyl-, inner salt,
Perifosine [INN],
NKA17,
C25H52NO4P,
D-21266,
PubChem22480,
AC1L3WLE,
DSSTox_CID_28872,
DSSTox_RID_83141,
DSSTox_GSID_48946,
SCHEMBL93872,
CHEMBL372764,
GTPL7424,
DTXSID3048946,
CTK8B6739,
KS-00000XOT,
AOB3006,
QCR-270,
BCP00245,
EX-A2229,
YHI-1003,
Tox21_113365,
ABP000409,
AN-933,
ANW-54211,
BDBM50431630,
MFCD00927554,
Perifosine/D21266 /D-21266,
s1037,
Piperidinium,1-dimethyl-, inner salt,
AKOS005146344,
CS-0209,
EX-3388,
GS-3834,
RL02027,
NCGC00187909-02,
4CA-0986,
AC-25019,
AM808092,
BR-48419,
HY-50909,
SC-27664,
AB0022540,
TC-061681,
CAS-157716-52-4,
FT-0083490,
FT-0651459,
ST24026716,
W3423,
A23834,
D21266,
S-7469,
139318-EP2270008A1,
139318-EP2292617A1,
Octadecyl-(1,1-dimethyl-4-piperidylio) phosphate,
I14-1991,
Perifosine; KRX-0401; NSC 639966; D21266,
1,1-dimethyl-4-{[(octadecyloxy)phosphinato]oxy}piperidin-1-ium,
4-[[Hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-piperidinium Inner Salt,
4-Hydroxy-1,1-dimethylpiperidinium hydroxide, octadecyl hydrogen phosphate, inner salt,
Pemetrexed,
D0R1VU,
cc-514,
C25-H52-N-O4-P,
CID148177,
ACN-038217,
KRX-0401, NSC 639966,
octadecyl-(1,1-dimethyl-4-piperidylio)phosphate,
A8309,
C105905,
octadec-yl-(1,1-dimethylpiperidinio-4-yl)phosphate,
Perifosine, 98%, an oral Akt inhibitor - 10MG 10mg,
4-[[Hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethylpiperidinium inner salt,
137281-23-3,